PHAR Stock Overview
Egyptian International Pharmaceutical Industries Company manufactures and distributes medicines, and medical and veterinary preparations in Egypt and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Egyptian International Pharmaceutical Industries Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ج.م41.81 |
52 Week High | ج.م53.49 |
52 Week Low | ج.م24.50 |
Beta | 0.22 |
1 Month Change | -12.90% |
3 Month Change | 6.63% |
1 Year Change | 24.29% |
3 Year Change | 1.90% |
5 Year Change | -44.34% |
Change since IPO | 647.71% |
Recent News & Updates
Recent updates
Shareholder Returns
PHAR | EG Pharmaceuticals | EG Market | |
---|---|---|---|
7D | -10.6% | -7.8% | -11.5% |
1Y | 24.3% | 27.3% | 47.9% |
Return vs Industry: PHAR underperformed the EG Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: PHAR underperformed the EG Market which returned 52.8% over the past year.
Price Volatility
PHAR volatility | |
---|---|
PHAR Average Weekly Movement | 6.4% |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 8.8% |
10% most volatile stocks in EG Market | 13.3% |
10% least volatile stocks in EG Market | 4.7% |
Stable Share Price: PHAR has not had significant price volatility in the past 3 months.
Volatility Over Time: PHAR's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | n/a | Ahmed Saeed Killani | www.eipico.com.eg |
Egyptian International Pharmaceutical Industries Company manufactures and distributes medicines, and medical and veterinary preparations in Egypt and internationally. It produces various dosage forms, such as spansule capsules, soft gelatin capsules, lyophilized products, gels, sprayers, and effervescent tablets, as well as antibiotics. The company also provides Covid-19 related protocol medicine, including epicehin, epizithro, cetal, dexamethasone, and cevitil.
Egyptian International Pharmaceutical Industries Company Fundamentals Summary
PHAR fundamental statistics | |
---|---|
Market cap | ج.م6.22b |
Earnings (TTM) | ج.م822.32m |
Revenue (TTM) | ج.م5.23b |
7.6x
P/E Ratio1.2x
P/S RatioIs PHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHAR income statement (TTM) | |
---|---|
Revenue | ج.م5.23b |
Cost of Revenue | ج.م2.98b |
Gross Profit | ج.م2.25b |
Other Expenses | ج.م1.43b |
Earnings | ج.م822.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 5.53 |
Gross Margin | 42.98% |
Net Profit Margin | 15.72% |
Debt/Equity Ratio | 115.4% |
How did PHAR perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield18%
Payout RatioDoes PHAR pay a reliable dividends?
See PHAR dividend history and benchmarksEgyptian International Pharmaceutical Industries dividend dates | |
---|---|
Ex Dividend Date | Apr 28 2024 |
Dividend Pay Date | Aug 29 2024 |
Days until Ex dividend | 3 days |
Days until Dividend pay date | 126 days |
Does PHAR pay a reliable dividends?
See PHAR dividend history and benchmarks